|
NEW JERSEY-BASED CRO’S EXODON AND PRIMERA FORM ALLIANCE |
|
Exodon LLC and Primera Analytical Solutions Corp., New Jersey-based clinical research firms headquartered in Mt. Arlington and Princeton, respectively, have entered into a non-exclusive strategic alliance agreement.
Exodon offers beginning-to-end early drug, biologic and nutraceutical development services from its clinical research units in the U.S., India, the Philippines, and Argentina. Exodon’s early drug and nutraceutical development includes multinational regulatory filings, PK/PD, BA/BE, and Phase I - IIb clinical trials. Late phase development includes site selection and patient recruitment and study management for clinical trials at its SMO and TMO sites
Primera specializes in providing bioanalytical, analytical, formulation and clinical trial analysis services for the pharmaceutical, biotechnology, agrochemical, cosmetic and dietary supplement industries. Specific services include method feasibility, development, validation, method transfer and sample analysis.
“This new business relationship will enable Exodon and Primera to jointly offer a range of services that would not be possible individually,” said Gerald Tramontano, Ph.D., Vice President, Clinical Research Operations at Exodon.
“Together, it will also allow us to offer better pricing options to our early pharmaceutical and nutraceutical clients given laboratory costs eat up a significant amount of the study budget for these types of trials,” added Paul Ernest de Leon, Director of Business Development for Exodon’s Product R&D department.
For example, this will allow Exodon to conduct such study requirements as method development, chemical validation and stability tests, and will provide Primera with applicable clinic-related assistance and facility for its research studies.
Exodon's mission is to transform research participation into an everyday connection for patients, doctors and clients.
Primera partners with its clients in a variety of ways. The company provides customized analysis for individual studies, functions as the virtual QC department for stability assessment and product release, and performs strategic consulting in clinical trial feasibility and design.
Contact: Steven Clark/Howard Matzner
Andover Communications
Phone: (201) 947-4133
Email: sclark@andovercommunications.com
|
|
|
